Policy & Regulation
WuXi Biologics wins at 2026 Asia-Pacific Biopharma Excellence Awards for leadership in bioprocessing, manufacturing excellence, and digital innovation
13 March 2026 -

WuXi Biologics ('WuXi Bio') (HK:2269), a global Contract Research, Development and Manufacturing Organization (CRDMO), announced on Thursday that it has received six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excellence Awards (ABEA).

WuXi Biologics was named the winner in the following six categories: Best Contract Development & Manufacturing Organization Award, Best Aseptic Fill-Finish & Packaging CMO of the Year, Bioprocessing Excellence in Asia, Bioprocessing Excellence in China, Bioprocessing Facility of the Year, and Excellence in Bioprocessing Automation & Digitalization.

Additionally, WuXi Bio's chief technology officer, executive vice president, Dr. Sherry Gu, was named CTO of the Year and Dr. Jeremy Guo, head of Global Drug Product Operations, senior vice president, received the award of Head of Fill-Finish & Formulation of the Year.

Login
Username:

Password: